Addressing Inequalities in Global Diagnostics Supply

Global Access Diagnostics (GADx), created to address gaps in the global provision of diagnostic supplies has been introduced by social enterprise Global Access Health (GAH) as its first portfolio company. Combing expertise in rapid diagnostics development from Mologic Ltd with low-cost manufacturing and scale-up capability of sister company, Global Access Diagnostics (GAD), GADx will re-invest all surplus to deliver quality and affordable diagnostics to those in most need. This includes transferring diagnostic technology to low-middle income countries, delivering tests such as COVID-19 to communities in need and developing tests for neglected diseases such as dengue, bilharzia, and river blindness. It is a unique initiative set up and supported by GAH which was formed in 2021 by a group of philanthropic funds and investors led by the Soros Economic Development Fund (SEDF), with support from the Bill & Melinda Gates Foundation. Through this transaction, the group acquired Mologic and GAD combining industry-leading expertise under the GADx single brand, advancing the organisation’s philanthropic goals to maximise its contribution to global healthcare.

In addition to its product portfolio, GADx offers expertise for contract research and development, support for companies, moving towards scale-up manufacturing (prototyping to pilot-scale) with capacity to produce over 2 million test per day, as well as manufacturing and logistics.  .

“Nearly half of the world’s population have little or no access to diagnostics; and only 1-in-5 people in low and low-middle income countries have basic diagnostic tests available to them," said Mark Davis, CEO of GADx R&D (formerly Mologic). He added: “GADx’s foundation is based on three pillars: leadership in research and development, manufacturing prowess and Our Core Mission: reinvesting surplus. We are building an innovative social enterprise that puts underserved communities above shareholders and aims to create legacies that bring sustainable change to healthcare and business.” 

Sumin Koo, CEO of GAH, commented: “To be a leader in R&D, we brought in Mologic, a pioneer in rapid diagnostics and  a participant in over 150 international research projects, working with globally recognised partners. The team’s expertise and products are at the forefront of human, animal, and agriculture diagnostics.This is paired with the strength of GAD’s novel manufacturing platform; holding the flexibility and expertise to accommodate one-off orders and scale-up for mass production, of over 1million tests per day.”

Mark Radford, CEO of GADx Manufacturing (formerly GAD), added: “This is an exciting next step for GADx, harnessing our individual expertise in lateral flow testing to transform rapid diagnostics. We have very well-established contract manufacturing capabilities to provide custom, flexible and scalable solutions, from low- to high-volume. This single brand portrays our group vision for the future of diagnostic testing; we look forward to progressing this to get the best tests to the most people, for the lowest cost and do so sustainably.”

More information online